Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions
Journal of Clinical Microbiology · 10.09.2025 · 63 (9)
DOI: 10.1128/jcm.01623-23 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Microbiology, erschienen am 10.09.2025. Verfasst von Audrey N Schuetz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing (AST) publishes annual updates to the M100 Performance Standards for Antimicrobial Susceptibility Testing . This important document contains key information critical to the laboratory’s performance of accurate and current AST. This minireview will highlight and provide supporting data for major changes in the M100 32nd and 33rd editions published in February 2022 and March 2023, respectively. New and revised breakpoints for gram-negative and gram-positive organisms are explained. Proper use of the restructured M100 Table 1 guidance for antimicrobial agents to be considered for testing and reporting is outlined. Reporting guidance for multidrug-resistant gram-negative bacilli is discussed. Other topics within this minireview include additional agents to test and report for direct blood disk diffusion of gram-negative bacilli and quality control range changes and troubleshooting. The minireview concludes with other issues under consideration by the AST Subcommittee.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
- R&D, BD Life Sciences, Sparks, Maryland, USA.
- Public Health Laboratories, Los Angeles County Department of Public Health, Los Angeles, California, USA.
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pathology and Laboratory Medicine, Penn State Hershey Medical Center, Hershey, Pennsylvania, USA.
- Deparment of Pathology, Division of Clinical Pathology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
ORCID-Profile: Audrey N Schuetz, Andrea Ferrell, Romney Humphries, April M Bobenchik
Zitieren
APA
Schuetz, A. N., Ferrell, A., Hindler, J. A., Humphries, R., & Bobenchik, A. M. (2025). Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions. Journal of Clinical Microbiology, 63(9). https://doi.org/10.1128/jcm.01623-23
Vancouver
Schuetz AN, Ferrell A, Hindler JA, Humphries R, Bobenchik AM. Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions. Journal of Clinical Microbiology. 2025;63(9). doi:10.1128/jcm.01623-23
BibTeX
@article{Schuetz2025,
author = {Schuetz, Audrey N and Ferrell, Andrea and Hindler, Janet A and Humphries, Romney and Bobenchik, April M},
title = {Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions},
journal = {Journal of Clinical Microbiology},
year = {2025},
volume = {63},
number = {9},
doi = {10.1128/jcm.01623-23}
}
EUVIMED